Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study
Year: 2020
Type: article
Study design: Observational Study
Source: Blood
Authors: Narendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, Tamara K. Moyo, Lauren Shea, Nishitha Reddy, Julia Sheets, David M. Weiner, Praveen Ramakrishnan Geethakumari, Malathi Kandarpa, Ximena JordanBruno, Colin Thomas, Michael C. Churnetski, Andrew Hsu, Joseph Maakaron, Paolo Caimi, Pallawi Torka, Celeste Bello, Cherie Tan, Kevin A. David, Kathryn Lindsey, Irl Brian Greenwell, Murali Janakiram, Adam J Olszewski, Jonathon B. Cohen, Neil Palmisiano, Elvira Umyarova, Ryan A. Wilcox, Farrukh T Awan, Stefan K. Barta, Natalie S Grover, Nancy L. Bartlett, Yazeed Sawalha, Beth A. Christian, Alex F. Herrera, Geoffrey Shouse
Institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Washington University in St. Louis, Vanderbilt University Medical Center, University of North Carolina at Chapel Hill, University of Pennsylvania, The University of Texas Southwestern Medical Center, University of Michigan, University of Vermont, Thomas Jefferson University, Emory University, Winship Cancer Institute, Brown University, University of Minnesota, University Hospitals of Cleveland, University Hospitals Seidman Cancer Center, Roswell Park Comprehensive Cancer Center, Moffitt Cancer Center, Rutgers Cancer Institute, Medical University of South Carolina, MUSC Hollings Cancer Center, University of Minnesota Rochester, University of Vermont Medical Center, U-M Rogel Cancer Center, Abramson Cancer Center, UNC Lineberger Comprehensive Cancer Center, Alvin J. Siteman Cancer Center, City Of Hope National Medical Center, City of Hope
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3096884015